ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
Empagliflozin offers cardiorenal benefits for up to 12 months after discontinuation among CKD patients at risk for progression
Clinical Practice Guidelines Updated for Primary Prevention of Stroke
Recommendations include screening for and addressing adverse social determinants of health
Inhaled Nicotine Disrupts Normal Heart Function
Effects seen in rats in recent study
ASA: Fibrinogen-to-Albumin Ratio Is Risk Factor for Preeclampsia
FAR was one of only two markers that were significant in predicting both PE and PE with severe features
Knowledge of Abdominal Aortic Calcification Results Improves Some CVD Risk Factors
Findings show no impact on fruit, veggie intake, but some improvement in cholesterol levels and cardiovascular risk scores
Risk for Sudden Cardiac Death Elevated for Patients With Psychiatric Disorders
Highest rates of SCD seen for patients with schizophrenic disease; 10-year excess loss of life expected for 18-year-olds with psychiatric disorder
FDA Appoints New Head of Medical Devices
Exposure to Inorganic Arsenic in Drinking Water Increases Cardiovascular Risk
Risk for ischemic heart disease elevated even at exposure levels below the current regulatory limit of 10 µg/L
Adult Hypertension Prevalence 47.7 Percent From August 2021 to August 2023
Hypertension increased with age, from 23.4 percent for those aged 18 to 39 years to 71.6 percent for those aged 60 years and older
Poor Cardiovascular Health Linked to Composite of Poor Brain Health
Individuals with poor or intermediate cardiovascular health have increased risk for composite of stroke, dementia, late-life depression
